USER FOCUS
At Haselmeier, our mission is to create products enabling a convenient and comfortable experience. This is why patient feedback is integrated early in our device designs. Early concepts are prototyped for testing and Human Factors studies to capture the handling needs and skills of potential users. This knowledge is integrated into the device design to provide successful administration of the drug product and a positive user experience.

BRIDGE TO MARKET
Successful development and industrialization of drug delivery devices is dependent upon the understanding and execution of today’s technical, regulatory and operational requirements. At Haselmeier we provide integrated design, development and industrialization services to help you bridge your serial product into the market. Our qualified design control process, certified quality system, regulatory expertise, solid network of partners and strong manufacturing operations are all designed to achieve your expectations. Together we enable a smooth market introduction for your commercial drug delivery device. 

MANUFACTURING & LIFECYCLE PARTNER
We understand that each customer has individual and specific requirements for their product. Regardless of your requirements, Haselmeier applies the highest quality standard for manufacturing your drug delivery device to ensure a reliable and reproducible manufacturing and quality process. We work continuously with our customers to identify product improvements at all stages of the product’s lifecycle to provide a safe and state-of-the art drug delivery device.

Drug Delivery. Tailormade.

Advertorial

Go to article: Home | Invest in TechGo to article: In this issueGo to article: Gerteis Company InsightGo to article: GerteisGo to article: ContentsGo to article: DJAGo to article: NewsGo to article: MedelpharmGo to article: Biotech M&A: will the 2018 surge last?Go to article: NSFGo to article: Can the gene and cell therapy revolution scale up?Go to article: Haselmeier GmbH Company InsightGo to article: Haselmeier GmbH Go to article: Gut instinct: how common drugs affect the microbiomeGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Tracing the story of mumps: a timelineGo to article: Molnar Company InsightGo to article: MolnarGo to article: Inside Swiss pharma: the ideal environment for successGo to article: Is the UK’s drug evaluation system in need of an overhaul?Go to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: MoehsGo to article: Could digital tech unlock billions in savings for pharma companies?Go to article: EcocoolGo to article: CRISPR: a seismic shift in gene editingGo to article: Mestra AG (Endress + Hauser)Go to article: EventsGo to article: Pfanstiehl Inc Company InsightGo to article: Pfanstiehl Inc.Go to article: Next issueGo to article: Niconex Medical LtdGo to article: Alpex Pharma SAGo to article: Pall Biotech Company InsightGo to article: Pall BiotechGo to article: AtoZ-CRO GmbHGo to article: WIKA - Disaster preventionGo to article: Bea TechnologiesGo to article: BaxterGo to article: SuezGo to article: Raland Compliance Partners